Product Related Literature

Ring squamous cell carcinoma is a histological variant of skin cancer (sometimes displayed as “squamous cell carcinoma signet ring”). As the name suggests, this is a subtype of squamous cell carcinoma, I is characterized by concentric circles made of vesicles that are substantially enlarged keratin, large vacuoles, the corresponding. These bubbles will rise to the extent that displacing the similarity of unique cell surface to the nucleus radical, “ring” of the cells to the plasma membrane when observed under a microscope. Signet ring cell carcinoma is a malignant epithelial tumor characterized by histological type of cell ring seal. It takes the form of adenocarcinoma, which is found in glandular cells of the stomach most commonly, but it also may occur in other areas of the body. For example. Interstitial testicular prostate, bladder, gall bladder, breast, colon, and ovary. In many cases, these cases and is inherited by (but not all) is caused by mutations in the gene CDH1 are some instances. Pattern of metastasis of gastric cancer cells with different printing than intestinal-type gastric cancer. When gastric cancer cells to transition the print, there is a tendency to create a Krukenberg tumor, spread to lymphocytic infiltration of ovarian peritoneal metastasis, lung and it.

The SCLC, may occur in a wide variety of combinations of histologic variants of other lung tissue containing complex malignant impurities very. If it is found in the form of a separate one or more of lung cancer such as adenocarcinoma and squamous cell carcinoma, malignant tumors, and then it was classified as (c in SCLC) mixed small cell lung cancer diagnosis and. Of SCLC, C non-small cell lung cancer, a subtype that is currently recognized. Synthesis SCLC is the current position, and are treated in the same manner as “clean” small-cell lung cancer, but recent studies have shown, the operation is able to improve performance in the early stages of this type of tumor .

Are as lung cancer and other symptoms. In addition, by the cell neuroendocrine origin of them, small cell carcinoma, and release substances that cause paraneoplastic syndromes such as Lambert-Eaton myasthenic syndrome such often. The main venue of small cell carcinoma, it is not a very rare outside of the pleural cavity and lung, it is called (EPSCC) small cell lung cancer. Outside of the respiratory tract, small cell carcinoma, can occur in the bladder cervix, prostate, liver, pancreas, or gastrointestinal tract,. Thought to consider a new case 1,000 per year in the United States that is histologically similar small cell lung cancer, the treatment of small cell lung cancer, it is used to treat EPSCC typically. Line initial therapy in general with etoposide and cisplatin. In Japan, the first-line treatment, transition to cisplatin and irinotecan.

Main spot of the skin when a Merkel cell carcinoma more. Small cell lung cancer is divided into two phases comprising (ES) stage a limited clinical pathological long and rich stage (LS). Tumors is shown only from the chest generally by step, whether or not it is that can be incorporated into the portal radiotherapy single total weight of the breast tumors practice is determined by the presence or absence of metastases. If it is limited to the lymph nodes near the lung and lung tumors one, it is said in general, and LS. If you have cancer spread beyond it, the ES is said.  In the case (in many cases, including paclitaxel cyclophosphamide, cisplatin, doxorubicin, etoposide, vincristine and / or) of LS-SCLC, combination therapy, I was administered together (RT) and concurrent thoracic radiotherapy.

Between 75% of people indicating the (CR) “complete remission” and 45% initial objective response rate very high between the observed using the LS-small cell lung cancer chemotherapy 90% from 60% ( It is defined as the disappearance of radiological evidence of clinical and all RR), of a tumor. Unfortunately, recurrence is the rule, the median survival is 24 months from 18 months. Under most circumstances, has spread widely in the natural history of the tumor at a very early stage, to respond dramatically in almost all cases, SCLC is or RT / CT, the role of little for surgery in 1970 this disease It is from the year. However, a recent study, when used before chemotherapy, in the case of (“very limited”) small asymptomatic, node-negative SCLC-san, surgical resection survival Improving was suggested. (“Adjuvant”).

The ES-SCLC, the combination chemotherapy, the standard treatment of radiation therapy, if temporary, shortness of breath, such as have faster than normal, and pain caused by bone metastases and liver, SCLC is for the treatment of brain metastases responses to whole brain radiation therapy were added only to alleviate symptoms such as.  Combination therapy is composed of cisplatin, cyclophosphamide, vincristine and carboplatin and, from a variety of agents. 30% of patients had a complete response to combination chemotherapy and 15%, response rate is also high for a wide range of disease among the majority of response objective of at least some.

However, in many cases, the response of ES-SCLC short time. If it occurs in the target having a small cell lung cancer complete response to chemotherapy, (PCI), is used to prevent the development of brain metastases often prophylactic cranial irradiation after. This treatment is very effective, but it can cause fatigue and hair loss. Adverse effect was not observed at all in the prospective randomized trial with 2 year follow-up neurocognitive almost. A meta-analysis of the PCI confirmation randomized trial, it provides a significant advantage for survival. Finally, small cells are very sensitive to radiation therapy and chemotherapy, platinum-containing agents, in particular, basic circuit. However, most people with median survival and disease relapse remains low.